SynthesisScience progress
The effectiveness of congenital toxoplasmosis treatment in minimizing hearing loss: A systematic review.
Synthesis in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCongenital toxoplasmosis is a condition caused by
methodsThe review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was registered in Prospero under the number CRD42024581716. Defined according to the PICO strategy (P: population/patients; I: intervention/exposure; C: comparison/control; O: outcome), a search was conducted on 29 August 2024, in the following databases: Embase, Lilacs, PubMed, SciELO, Scopus, and Web of Science.
resultsOf the 396 studies initially identified, 10 met the inclusion criteria, and 2 additional studies were included through manual search, totaling 12 articles for the review. The selected articles lacked standardization regarding therapeutic protocols, with most studies being from Brazil, where the regimen of sulfadiazine, pyrimethamine, and folinic acid for 1 year is recommended. Moreover, despite region-specific therapeutic schemes, a considerable portion of cases still exhibited auditory sequelae, suggesting a potential inefficacy of the implemented protocols.
conclusionsThere are a small number of studies on the treatment of toxoplasmosis, and its effects on avoiding hearing outcomes are understudied. Locally, there is a need to establish good outcomes and targets to intervene. Strategies to improve adherence to long-term treatment, adjusts to the therapeutic protocol, alongside the promotion of research on the efficacy of treatments for specific outcomes of toxoplasmosis are necessary, especially in places where more virulent strains can be responsible for more aggressive infections and worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.